Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Phillip Kempf

Rheumatology Arlington, VA Medical Doctor

NPI 1386662286 CMS profile 17086

1635 N George Mason Dr Ste 220, Arlington, VA 22205

Open in the dashboard

General payments

$321,283

1,179 records reported · program years 2019–2024

Research payments

$1,314

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$145,929 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Phillip Kempf of Arlington, VA is reported in the CMS Open Payments database as having received $321,283 across 1,179 general payments and $1,314 in research payments paid to them. Separately, studies naming them as principal investigator received $145,929 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $10,848 17
2023 General $27,233 174
2022 General $56,423 268
2021 General $46,057 194
2020 General $50,478 150
2020 Research $153 1
2019 General $130,243 376
2019 Research $1,161 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phillip Kempf
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Phillip Kempf were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Phillip Kempf Rheumatology median Middle half National median
2019 $130,243 $744 $153–$2,687 $163
2020 $50,478 $462 $98–$2,027 $114
2021 $46,057 $531 $101–$2,153 $132
2022 $56,423 $627 $125–$2,303 $149
2023 $27,233 $741 $145–$2,524 $160
2024 $10,848 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $64,960 167 payments
  2. Mallinckrodt Hospital Products Inc. $59,004 90 payments
  3. UCB, Inc. $54,077 189 payments
  4. Amgen Inc. $26,914 126 payments
  5. Horizon Therapeutics plc $21,622 60 payments
  6. AstraZeneca Pharmaceuticals LP $16,512 53 payments
  7. Pfizer Inc. $15,383 59 payments
  8. Celgene Corporation $14,334 43 payments
  9. Mallinckrodt Enterprises LLC $14,018 23 payments
  10. GlaxoSmithKline, LLC. $9,022 43 payments
  11. Other $25,437 326 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $213,008 103 payments
  2. Consulting Fee $35,322 17 payments
  3. Travel and Lodging $27,559 165 payments
  4. Food and Beverage $25,828 882 payments
  5. Honoraria $19,340 7 payments
  6. Education $186 4 payments
  7. Gift $41 1 payment
Products named General payments · program years 2019–2024
  1. ACTHAR Immunology $59,004 90 payments
  2. Cimzia $54,077 189 payments
  3. RINVOQ $52,083 129 payments
  4. KRYSTEXXA $21,444 50 payments
  5. Otezla Inflammation $17,078 32 payments
  6. SAPHNELO $16,512 53 payments
  7. Otezla Dermatology $14,334 43 payments
  8. ACTHAR Autoimmune And Rare Disease $14,018 23 payments
  9. XELJANZ $10,688 52 payments
  10. BENLYSTA $9,022 43 payments
  11. Other $56,909 693 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $1,314 2 payments

Records

1,181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record